Zentalis Pharmaceuticals ZNTL 深 沪
已收盘 12-19 16:00:00 美东时间
1.405
-0.015
-1.06%
华盛通- 最 高1.48
- 今 开1.41
- 成交量 66.12万股
- 最 低 1.31
- 昨 收 1.42
- 总市值 7855.90万
- 52周最高 3.33
- 市盈率 静 --
- 换手率 1.18%
- 52周最低 1.01
- 委 比 43.08%
- 总股本 5591.39万
- 历史最高 87.19
- 量 比 0.45
- 振 幅 11.97%
- 历史最低 1.01
- 每 手 1
- 风险率 0.48%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Zentalis Pharmaceuticals granted stock options to four new employees in June 2025, with 137,400 shares under its 2022 Inducement Plan. The options have an exercise price of $1.28 per share, vest over four years, and are contingent on continued employment. Zentalis focuses on developing a first-in-class WEE1 inhibitor for ovarian cancer.
06-02 21:00
Oppenheimer Reiterates Outperform on Zentalis Pharma, Maintains $20 Price Target
Oppenheimer analyst Matthew Biegler reiterates Zentalis Pharma (NASDAQ:ZNTL) with a Outperform and maintains $20 price target.
2024-09-17 01:52
Market-Moving News for September 16th
NCNA: 282% | NuCana Presented Final Data From Phase 2 Nutide:701 Study At ESMO Congress On NUC-7738 In Combination With Pembrolizumab For Patients With Metastatic Melanoma Who Were Refractory To Or Had Relapsed On
2024-09-16 20:08
Zentalis Says It Remains On Track To Meet All Previously Disclosed Data Guidance For Remainder Of 2024
At a corporate event later this year, Zentalis will present azenosertib monotherapy data and provide additional updates to azenosertib clinical development and other data presentation timelines.
2024-09-16 19:08
